MOUNJARO 10 mg (Tirzepatide PFS) 10 mgx0.5 ml

Tirzepatide, the active ingredient in MOUNJARO 10 mg, is a dual agonist of glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors. This mechanism enhances insulin secretion, suppresses glucagon secretion, slows gastric emptying, and reduces appetite, thereby improving glycemic control.

The usual starting dose of MOUNJARO 10 mg is 2.5 mg injected subcutaneously once weekly. The dose can be increased in 2.5 mg increments every 4 weeks as needed, up to a maximum dose of 15 mg once weekly. The prescriber will determine the appropriate dosage based on the patient's response and tolerance.

The safety of MOUNJARO 10 mg during pregnancy or breastfeeding has not been established. It is important to consult with a healthcare provider before using this medication if you are pregnant, planning to become pregnant, or breastfeeding.

To order MOUNJARO 10 mg from GNH India, submit an enquiry on the product page at gnhindia.com with the required quantity. GNH India supplies hospitals, pharmacies, and procurement teams across international markets. The team will ask you to confirm your trade or institutional credentials and will then provide pricing, availability, shipping, and the necessary import paperwork.

MOUNJARO 10 mg is a dual GIP/GLP-1 receptor agonist, which distinguishes it from other diabetes medications that may only target one of these receptors. This dual action can provide more comprehensive glycemic control and additional benefits such as weight loss and reduced appetite.

MOUNJARO 10 mg should be stored in a refrigerator at 2-8°C (36-46°F). If needed, it can be stored unrefrigerated at temperatures not exceeding 30°C (86°F) for up to 21 days. It should be kept in the original carton to protect from light and should not be frozen or shaken.

MOUNJARO 10 mg is administered subcutaneously once weekly. It can be injected into the abdomen, thigh, or upper arm. The injection should be done at the same time each week, with or without meals, as directed by the healthcare provider.

The most serious risks associated with MOUNJARO 10 mg include pancreatitis, hypoglycemia, kidney problems, allergic reactions, and gallbladder problems. Patients should be monitored for signs of these conditions and should seek medical attention if any severe symptoms occur.

MOUNJARO 10 mg should not be used by individuals with a personal or family history of medullary thyroid carcinoma, multiple endocrine neoplasia syndrome type 2, or those with a history of severe gastrointestinal disease. It is also not recommended for use in patients with type 1 diabetes mellitus or diabetic ketoacidosis.